Overview Phase III Trial of Stage I Ovarian Cancer After Surgery Status: Recruiting Trial end date: 2030-02-01 Target enrollment: Participant gender: Summary To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery Phase: Phase 3 Details Lead Sponsor: Japanese Gynecologic Oncology GroupCollaborator: Korean Gynecologic Oncology GroupTreatments: Albumin-Bound PaclitaxelCarboplatinPaclitaxel